首页 News 正文

Publicity of prescription drugs in public places, Baekje Shenzhou Cooperation Company fined 400000 yuan

sxhe
3666 0 0

On January 19th, Red Star Capital Bureau reported that according to the official website of the Shanghai Municipal Administration for Market Regulation, Baekje Shenzhou (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Baekje Shenzhou Biotechnology") has recently been fined 400000 yuan for using advertisements to falsely promote goods or services.
After investigation, it was found that BeiGene Biotech was entrusted by BeiGene (688235. SH; 06160. HK; BGNE. US) to be responsible for the marketing of Pamipali capsules. However, according to public information, there is currently no equity relationship between the two companies.
On January 19th, BeiGene responded to the Red Star Capital Bureau that the company would take it as a warning and strictly comply with relevant laws and regulations in its future work.
On August 18, 2022, BeiGene Biotech held the "Baihuize City Conference" and during the conference, published an advertisement for Pamipali capsules in public areas using a flip flop and promotional flyer as carriers, claiming that "Baihuize (Pamipali) is the only PARP inhibitor approved for the treatment of 3L gBRCAm platinum sensitive and platinum resistant recurrent ovarian cancer; CGCS guidelines recommend Pamipali as the preferred drug for the treatment of recurrent ovarian cancer; the monthly treatment cost for medical insurance patients is only 1929 yuan.".
Data shows that Pamipali capsules are used for the treatment of recurrent advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer patients who have undergone second-line or above chemotherapy and have germline BRCA (gBRCA) mutations.
But as a prescription drug, it can only be advertised in medical and pharmaceutical professional journals jointly designated by the health administrative department of the State Council and the drug regulatory department of the State Council.
On September 21, 2022, with approval, an investigation was filed into the illegal advertising behavior of BeiGene Biotech.
The Market Supervision Administration of Jing'an District, Shanghai believes that Baekje Shenzhou Biotechnology promotes the above-mentioned prescription drugs in public places through the form of pull-up banners and promotional leaflets. The advertising target audience is not specific and will have an impact on the choices of ordinary patients and consumers without professional medical and pharmaceutical knowledge. It cannot guarantee the scientific, correct, reasonable, and safe use of drugs. Finally, BeiGene Biotech received the Administrative Penalty Hearing Notice on December 27, 2023.
Red Star News reporter Deng Lingyao
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   苹果知名分析师郭明錤周四(10月31日)在社交媒体上发文表示,苹果明年可能会减少对芯片制造商博通Wi-Fi芯片的依赖,并推出自己的处理器。   郭明錤在社交媒体平台X上写道,“在2025年下半年的新产品(例如iPh ...
    uturn
    昨天 14:42
    支持
    反对
    回复
    收藏
  •   10月30日,小鹏汽车生态企业小鹏汇天宣布,旗下分体式飞行汽车“陆地航母”即将亮相2024中国航展,11月12日将在中国航展第二展区(斗门莲洲)进行全球首次公开飞行,同时“陆地航母”也将在珠海国际航展中心8号 ...
    yxtianyouyou
    前天 11:43
    支持
    反对
    回复
    收藏
  •   交易所监管文件显示,当地时间11月1日,亚马逊创始人杰夫·贝索斯拟出售约1635万股亚马逊股票,预计套现约30.5亿美元。今年7月,贝索斯已申请额外出售约2500万股亚马逊股票,按当时股价计算可套现约50亿美元。 ...
    blueskybb
    13 小时前
    支持
    反对
    回复
    收藏
  •   近日,凯撒海湾目的地(山东)运营管理有限责任公司(简称“凯撒海湾”)与携程旅悦集团签署战略合作协议,双方将围绕“海上目的地运营”、“旅游产品与服务创新”、“研学旅行”、“日韩及海外旅游市场开拓”等 ...
    llyyy2008
    11 小时前
    支持
    反对
    回复
    收藏
sxhe 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    0